Analytical Data
-
Gene name
cobratoxin
- Application
-
Alternative Names
Alpha-elapitoxin-Nk2a Short name:Alpha-EPTX-Nk2a Long neurotoxin 1 Siamensis 3
-
Species
Naja kaouthia
-
Source
E. coli
-
Tag
N- His-GST & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01391
-
Expression Region
1-71aa
-
Molecular Weight
37.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cobra venom-based proteins, particularly cobratoxin (CTX), have garnered significant attention in the field of pharmacology and toxicology due to their unique neurotoxic properties. CTX is a polypeptide derived from the venom of certain cobra species, notably the Thai cobra (Naja kaouthia). It primarily acts as a presynaptic neurotoxin, inhibiting the release of acetylcholine at the neuromuscular junction, which leads to paralysis and respiratory failure in prey. Recent research has focused on the potential therapeutic applications of cobratoxin and its recombinant protein forms, as its mechanism of action could offer insights into neuromuscular disorders, pain management, and the development of novel analgesics. Moreover, the recombinant production of cobratoxin allows for the generation of high-purity, scalable proteins, minimizing the ethical concerns associated with animal-derived venoms. Additionally, the study of CTX and its analogs can facilitate the understanding of synaptic transmission and contribute to the design of drugs targeting neurotransmitter systems. Researchers are exploring its role in the modulation of ion channels and neurotransmitter receptors, as well as its potential as a tool for probing neurological pathways. Overall, cobratoxin's diverse biological effects and its potential for therapeutic exploitation position it as a valuable asset in the advancement of neuroscience and therapeutics.
